We aspire to make a lasting impact for patients with cardiac diseases
Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.
Scientific Advisory Board
Cardior is supported by a range of prestigious life science investors.
We have established successful relationships with renowned academic partners and are always looking for new collaboration opportunities to further advance our innovative therapy approach.